Subscribe to our monthly newsletter to receive exclusive news updates and medical AI insights.
The ADAPT Study: Assessment of the DiAgnostic Performance of DeepVessel FFR in SuspecTed Coronary Artery Disease SUMMARY DEEPVESSEL FFR is a medical device that is designed to extract three- dimensional coronary tree structures and generate computed tomography-derived...
New data from the TARGET trial, the first randomized trial to assess on-site machine learning-based CT-FFR strategy in CAD management.
Deep-learning-based, non-invasive, accurate, and accessible FFR CT analysis DEEPVESSEL FFR is now available in the USA.
The future of AI-driven, noninvasive CT FFR technology-DeepVessel FFR at 2022 cardiology events in China
Keya Medical US celebrates the achievements of the team in China and their commitment to the commercialization of DEEPVESSEL FFR.
DEEPVESSEL FFR, Keya Medical Deep-Learning Based, Non-Invasive Coronary Artery Functional Assessment Software Device, Receives FDA Clearance.
Seattle, WA– April 1, 2022– Keya Medical announced that DEEPVESSEL FFR (DVFFR), has been cleared by U.S. Food and Drug Administration (FDA).
Keya Medical’s computer scientists, working with colleagues at the Shenzhen Second People’s Hospital, have devised a new method that significantly boosts segmentation accuracy and performance.
GAIR2021 released the annual Best AI Digital Intelligence List. In the medical field, Keya Medical received the Best Clinical Aided Decision-Making Product Award for its flagship product DeepVessel FFR.
Coronary Artery Calcium (CAC) scores have become increasingly important in assessing risk for coronary artery disease. Although non-contrast CT scans are typically used for CAC scoring, calculating CAC scores from CTAs directly could add further value to CTAs as a...
The 2021 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain was released on 28 October 2021. This report represents years of work by the Joint Committee on Clinical Practice Guidelines to define protocols and algorithms based on the evidence.
On August 24, Keya Medical’s flagship product, DeepVessel FFR, was successfully implemented in Beijing Anzhen Hospital.
The future of health data interoperability using FHIR. ONC’s Micky Tripathi provided his perspective at a recent Cambia Grove forum.
Artificial intelligence and other advanced informatics could be applied to coronary CTA images to unlock valuable information on atherosclerotic plaque characteristics that could be used to personalize care decisions. Learn more.
Learn more about the encouraging recent developments in the use of targeted fee-for-service models as a transition strategy to ensure that patients have access to proven advanced diagnostics and treatments.